Last reviewed · How we verify
placebo to match tiotropium
This is an inert placebo formulation designed to match the physical and sensory characteristics of tiotropium inhalation powder for use in blinded clinical trials.
This is an inert placebo formulation designed to match the physical and sensory characteristics of tiotropium inhalation powder for use in blinded clinical trials. Used for Control arm in clinical trials of tiotropium for chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | placebo to match tiotropium |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Mechanism of action
Placebos contain no active pharmaceutical ingredient and produce no pharmacological effect. This particular placebo is engineered to mimic tiotropium's appearance, taste, inhalation device mechanism, and delivery characteristics to maintain blinding in randomized controlled trials, ensuring that neither patients nor researchers can distinguish it from the active drug based on sensory cues.
Approved indications
- Control arm in clinical trials of tiotropium for chronic obstructive pulmonary disease (COPD)
Common side effects
Key clinical trials
- Regular Use Tiotropium and Tolerance to Bronchoprotection in Mild Asthma (PHASE4)
- A Study to Test the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler in People With Chronic Obstructive Pulmonary Disease (COPD) Who Have Different Abilities to Inhale (PHASE4)
- An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler. (PHASE2)
- A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE4)
- A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease (PHASE2)
- A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE4)
- A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE4)
- The Effects of RPL554 in Addition to Tiotropium in COPD Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- placebo to match tiotropium CI brief — competitive landscape report
- placebo to match tiotropium updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI